PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32558923-9	2020	In conclusion, high-dose esomeprazole can cause strong inhibition of CYP2C19, but only weakly inhibits CYP3A4 and leads to minor induction of CYP1A2.	Esomeprazole	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109	
32558923-0	2020	Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19 and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.	Esomeprazole	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62	
23857299-9	2013	Omeprazole, esomeprazole and pantoprazole had greater effects on CYP3A4-mediated reactions, whereas lansoprazole was selective for CYP2D6-mediated formation of oxymorphone.	Esomeprazole	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71	
28875498-3	2018	CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan.	Esomeprazole	77-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18	
26661629-6	2016	We postulate that esomeprazole may have a mild inhibitory effect on CYP3A4, which leads to decreased metabolism of estrogen, thereby increasing serum estrogen levels.	Esomeprazole	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74	
16338278-10	2005	CONCLUSION: In contrast to other PPIs, esomeprazole-induced healing of GERD is unrelated to the CYP2C19 genotype, which can be explained by the metabolic shift toward the CYP3A4-mediated pathway.	Esomeprazole	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-177	
11475467-3	2001	In vitro experiments in human liver microsomes demonstrated that the formation of the hydroxy and 5-O-desmethyl metabolites of esomeprazole is via cytochrome P450 (CYP) 2C19, whereas that of the sulphone metabolite is via CYP3A4.	Esomeprazole	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	222-228	
34791831-3	2022	The aim of our study was to develop a physiologically based pharmacokinetic (PBPK) model to foresee the impact of elevated IL-6 levels in combination with drug interactions with esomeprazole on CYP3A and CYP2C19.	Esomeprazole	178-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-199	
34791831-9	2022	The impact of IL-6 and esomeprazole on the exposure to CYP3A and CYP2C19 probe substrates and respective metabolites were correctly predicted.	Esomeprazole	23-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-60	
34791831-11	2022	The impact of IL-6 and esomeprazole on CYP3A and CYP2C19 activities after a hip surgery were correctly predicted with the developed PBPK models.	Esomeprazole	23-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-44